alx-0171
mAbexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01483911)
Timeline
Indications
Mechanism of action
- Fusion glycoprotein F0INHIBITOR
Fusion glycoprotein F0 inhibitor
- RSV F-proteinImmunity, passive
RSV F-protein immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297692 ↗
Also known as
- alx-0171
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03468829 | Phase 2 | Jun 30, 2018 | Ablynx |
| NCT03418571 | Phase 2 | Mar 1, 2018 | Ablynx |
| NCT02979431 | Phase 2 | Dec 1, 2016 | Ablynx |
| NCT02309320 | Phase 1 | Nov 1, 2014 | Ablynx |
| NCT01909843 | Phase 1 | Aug 1, 2013 | Ablynx |
| NCT01875926 | Phase 1 | Jun 1, 2013 | Ablynx |
| NCT01483911 | Phase 1 | Dec 1, 2011 | Ablynx |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ablynx | For profit | 7 | 7 | 2 | 2011 |
1 organizations
Page 1 / 1